var data={"title":"Pegylated interferon (peginterferon) alfa-2a: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegylated interferon (peginterferon) alfa-2a: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6732?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegylated interferon (peginterferon) alfa-2a: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709197\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of serious disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon alfa-2a may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all, cases, these disorders resolve after stopping peginterferon alfa-2a therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206899\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pegasys;</li>\n      <li>Pegasys ProClick</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206900\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pegasys</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206919\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Interferon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206903\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C (monoinfection or coinfection with HIV): </b> SubQ: 180 mcg once weekly, duration of therapy varies with HCV genotype and concurrent HCV antivirals. <b>Note: </b>Use of peginterferon is not recommended in the HCV treatment guidelines (AASLD/IDSA 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Chronic hepatitis B: </b> SubQ: 180 mcg once weekly for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Missed dose:</i> If within 2 days of the usual day of administration, administer dose as soon as possible then resume prior schedule; if &gt;2 days after the usual day of administration then contact health care provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15043485\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C:</b> Manufacturer&rsquo;s labeling: Children &ge;5 years and Adolescents: SubQ: 180 mcg/1.73 m<sup>2</sup> x body surface area (BSA) once weekly (maximum dose: 180 mcg); duration of therapy varies with HCV genotype and concurrent HCV antivirals. <b>Note:</b> Use of peginterferon is not recommended in the HCV treatment guidelines (AASLD/IDSA 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Chronic hepatitis B:</b> Children &ge;3 years and Adolescents: SubQ: 180 mcg/1.73 m<sup>2</sup> x body surface area (BSA) once weekly for 48 weeks (maximum dose: 180 mcg); maintain pediatric dosage through the entire duration of therapy in patients who turn 18 years of age during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Missed dose:</i> If within 2 days of the usual day of administration, administer dose as soon as possible then resume prior schedule; if &gt;2 days after the usual day of administration then contract health care provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062247\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206904\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: 135 mcg once weekly; monitor for toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) requiring hemodialysis: 135 mcg once weekly; monitor for toxicity. If severe adverse reactions or laboratory abnormalities occur, may reduce dose to 90 mcg once weekly until adverse reactions resolve; if intolerance persists after dosage adjustment, discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206905\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment prior to initiation:</i> Contraindicated in autoimmune hepatitis, hepatic decompensation (Child-Pugh &gt;6 [class B and C]) in cirrhotic patients before treatment, and hepatic decompensation with Child-Pugh &ge;6 in cirrhotic HCV patients coinfected with HIV before treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment during treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: <b>Note:</b> Immediately discontinue therapy if hepatic decompensation (Child-Pugh &ge;6 [class B and C]) is observed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HCV: ALT progressively rising above baseline: Decrease dose to 135 mcg once weekly <b>and</b> monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately. Therapy may resume after ALT flare subsides.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HBV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ALT &gt;5 x ULN: Consider decreasing dose to 135 mcg once weekly or temporarily discontinuing <b>and</b> monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately. Therapy may resume after ALT flare subsides.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ALT &gt;10 x ULN: Consider discontinuing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: HCV, HBV: <b>Note:</b> Immediately discontinue therapy if hepatic decompensation (Child-Pugh &ge;6 [class B and C]) is observed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT &ge;5 but &lt;10 x ULN (for persistent or increasing elevations): Decrease interferon dose to 135 mcg/1.73 m<sup>2</sup> x BSA once weekly. Monitor weekly; further modify dose if needed until ALT stabilizes or decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT &ge;10 x ULN (persistent): Discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3022885\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dosage modifications for adverse reactions and/or toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Children </b>\n      <b>&ge;3 years and Adolescents: HBV: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Based on hematologic parameters:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 750 to 999/mm<sup>3</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 500 to 749/mm<sup>3</sup>: Decrease dose to 135 mcg/1.73 m<sup>2</sup> x BSA once weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 250 to 499/mm<sup>3</sup>: Hold dose until ANC &ge;1,000 cells/mm<sup>3</sup> then resume at 90 mcg/1.73 m<sup>2</sup> x BSA once weekly and monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;250/mm<sup>3</sup> (or febrile neutropenia): Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count 25,000 to &lt;50,000/mm<sup>3</sup>: Decrease dose to 90 mcg/1.73 m<sup>2</sup> x BSA once weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &lt;25,000/mm<sup>3</sup>: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Children &ge;5 years and Adolescents: HCV:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Based on hematologic parameters:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 750 to 999/mm<sup>3</sup>: Week 1 to 2: 135 mcg/1.73 m<sup>2</sup> x BSA once weekly; Weeks 3 to 48: No modification</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 500 to 749/mm<sup>3</sup>: Week 1 to 2: Delay or hold dose until ANC &gt;750/mm<sup>3</sup> then resume dose with 135 mcg/1.73 m<sup>2</sup> x BSA once weekly. Assess WBC weekly for 3 weeks to verify ANC &gt;750/mm<sup>3</sup>; Weeks 3 to 48: 135 mcg/1.73 m<sup>2</sup> x BSA once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 250 to 499/mm<sup>3</sup>: Week 1 to 2: Delay or hold dose until ANC &gt;750/mm<sup>3</sup> then resume dose with 90 mcg/1.73 m<sup>2</sup> x BSA once weekly; Weeks 3 to 48: Delay or hold dose until ANC &gt;750/mm<sup>3</sup> then resume dose with 135 mcg/1.73 m<sup>2</sup> x BSA once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;250/mm<sup>3</sup> (or febrile neutropenia): Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count 25,000 to &lt;50,000/mm<sup>3</sup>: Decrease dose to 90 mcg/1.73 m<sup>2</sup> x BSA once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &lt;25,000/mm<sup>3</sup>: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Children &ge;3 years and Adolescents: HCV, HBV: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depression (severity based on DSM-IV criteria</i> [similar to adult dosing adjustment recommendations]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild depression: No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule. For worsening depression, discontinue or reduce dosage to 90 mcg/1.73 m<sup>2</sup> x BSA once weekly or 135 mcg/1.73 m<sup>2</sup> x BSA once weekly. Consider psychiatric consultation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate depression: Decrease to 90 mcg/1.73 m<sup>2</sup> x BSA or 135 mcg/1.73 m<sup>2</sup> x BSA once weekly; evaluate once weekly with an office visit at least every other week. If depression remains stable, consider psychiatric evaluation and continue reduced dosing. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; continue reduced dosing or return to normal dose. For worsening depression, discontinue permanently and obtain immediate psychiatric consultation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe depression: Discontinue permanently. Obtain immediate psychiatric consultation. Utilize follow-up psychiatric therapy as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adults: HCV, HBV:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Based on hematologic parameters:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 500 to &lt;750/mm<sup>3</sup>: Decrease dose to 135 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;500/mm<sup>3</sup>: Suspend therapy until ANC &gt;1,000/mm<sup>3</sup>, then restart at 90 mcg once weekly; monitor ANC</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count 25,000 to &lt;50,000/mm<sup>3</sup>: Decrease dose to 90 mcg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &lt;25,000/mm<sup>3</sup>: Discontinue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depression (severity based on DSM-IV criteria): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild depression: No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule. For worsening depression, discontinue or reduce dosage to 90 mcg or 135 mcg once weekly. Consider psychiatric consultation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate depression: Decrease to 90 mcg or 135 mcg once weekly; evaluate once weekly with an office visit at least every other week. If depression remains stable, consider psychiatric evaluation and continue with reduced dosing. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; continue reduced dosing or return to normal dose. For worsening depression, discontinue permanently and obtain immediate psychiatric consultation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe depression: Discontinue permanently. Obtain immediate psychiatric consultation. Utilize follow-up psychiatric therapy as needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206881\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pegasys: 180 mcg/mL (1 mL); 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pegasys ProClick: 135 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pegasys ProClick: 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206867\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874941\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlRq+irVTCmIpmoyMaJtVyuA==&amp;TOPIC_ID=10136\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206883\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer in the abdomen or thigh. Rotate injection site. Administration should be done on the same day and at approximately the same time each week. The manufacturer only recommends use of the 180 mcg/mL vial and a 1 mL tuberculin syringe for administration to pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206882\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis B:</b> Treatment of adults with hepatitis B e antigen (HBeAg)-positive and HBeAg-negative chronic hepatitis B virus (HBV) infection who have compensated liver disease and evidence of viral replication and liver inflammation; treatment of pediatric patients 3 years and older with HBeAg-positive chronic HBV infection who are non-cirrhotic and have evidence of viral replication and elevations of serum alanine aminotransferase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy:</i> Treatment of adults with chronic hepatitis C (CHC) with compensated liver disease as part of a combination regiment with other hepatitis C virus (HCV) antiviral drugs; treatment of pediatric patients 5 years and older with CHC and compensated liver disease in combination with ribavirin. <b>Note: </b>Peginterferon regimens are no longer recommended in the HCV treatment guidelines (AASLD/IDSA 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Monotherapy (for patients with contraindications or who are intolerant to other HCV antiviral drugs):</i> Treatment (as a single agent) of chronic hepatitis C in patients with compensated liver disease in patients with contraindications or significant intolerance to other HCV antiviral drugs. <b>Note:</b> Use of peginterferon is not recommended in the HCV treatment guidelines (AASLD/IDSA 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Peginterferon alfa-2a alone or in combination with ribavirin without additional HCV antiviral drugs is not recommended for treatment of patients with chronic HCV who previously failed therapy with an interferon alfa. Peginterferon alfa-2a is not recommended for treatment of patients with CHC who have had solid organ transplantation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206872\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (adults: &le;56%; children and adolescents: 8%), headache (adults: 27% to 54%; children and adolescents: 21%), rigors (adults: 25% to 35%), insomnia (adults: 19%), anxiety (adults: &le;19%), irritability (adults: &le;19%), nervousness (adults: &le;19%), depression (adults: 18%), dizziness (adults: 16%; children and adolescents: 6%), pain (adults: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (adults: 18% to 23%; children and adolescents: 6%), pruritus (adults: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Growth suppression (children and adolescents, percentile decrease (&ge;15 percentiles), weight: [11% to 43%], height: [6% to 25%])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (adults: &le;24%; children and adolescents: 9%), vomiting (adults: &le;24%), anorexia (adults: 16% to 17%), abdominal pain (15% to 17%), diarrhea (adults: 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (adults: 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (adults, hepatitis B: 25% to 27%; children and adolescents: 10%; adults, hepatitis C: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (adults: 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (adults: &le;56%; children and adolescents: 9%), myalgia (adults: 37%), arthralgia (adults: 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (children and adolescents: 15%; adults: 4%), flu-like symptoms (children and adolescents: 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (37% to 54%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Lack of concentration (adults: 8%), memory impairment (adults: 5%), mood changes (adults: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (5% to 10%), dermatitis (adults: 8%), diaphoresis (adults: 6%), xeroderma (adults: 4%), eczema (adults: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (adults: 4%), hypothyroidism (adults: 3% to 4%), hyperthyroidism (adults: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite (children and adolescents: 6%), xerostomia (adults: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncology: Thrombocytopenia (adults: 5%), lymphocytopenia (adults: 3%), anemia (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (children and adolescents: 10%), liver decompensation (in CHC/HIV patients; adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Bacterial infection (adults: &le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (adults: 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (adults: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (children and adolescents: 9%), upper respiratory tract infection (children and adolescents: 8%), nasopharyngitis (children and adolescents: 6%), dyspnea (adults: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&le;1%, postmarketing, and/or case reports: Aggressive behavior, anaphylaxis, angina pectoris, angioedema, aplastic anemia, auditory impairment, autoimmune disorders, bipolar mood disorder, bronchiolitis obliterans, bronchoconstriction, cardiac arrhythmia, cerebral hemorrhage, chest pain, cholangitis, colitis, coma, corneal ulcer, dehydration, diabetes mellitus, dyspepsia, dyspnea on exertion, endocarditis, erythema multiforme major, exacerbation of hepatitis B, exfoliative dermatitis, gastrointestinal hemorrhage, graft rejection (hepatic, renal), hallucination, hearing loss, hematocrit decreased, hemoglobin decreased, hepatic insufficiency, hyperglycemia, hyperpigmentation, hypersensitivity reaction, hypertension, hypoglycemia, increased serum triglycerides, influenza, interstitial pneumonitis, limb abscess, liver steatosis, macular edema, mania, myocardial infarction, myositis, optic neuritis, pancreatitis, papilledema, peptic ulcer, peripheral neuropathy, pneumonia, psychiatric disturbance, psychosis, pulmonary embolism, pulmonary infiltrates, pure red cell aplasia, retinal cotton-wool spot, retinal detachment, retinal hemorrhage, retinal thrombosis (in artery or vein), retinopathy, rheumatoid arthritis, sarcoidosis, seizures, Stevens-Johnson syndrome, substance overdose, suicidal ideation, supraventricular arrhythmia, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, tongue discoloration, urticaria, vesiculobullous reaction, vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206886\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens-Johnson syndrome) to peginterferon alfa-2a, other alfa interferons, or any component of the formulation; autoimmune hepatitis; hepatic decompensation in cirrhotic patients (Child-Pugh score &gt;6, class B and C) before treatment; hepatic decompensation with Child-Pugh score &ge;6 in cirrhotic CHC coinfected with HIV before treatment; neonates and infants (due to benzyl alcohol component)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Combination therapy with peginterferon alfa-2a and ribavirin is also contraindicated in pregnancy; men whose female partners are pregnant; patients with hemoglobinopathies (ie, thalassemia major, sickle cell disease); coadministration with didanosine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for interferons is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206870\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias; alfa interferons may (rarely) cause aplastic anemia. Ribavirin may potentiate these effects. When used in combination with ribavirin, use caution with baseline neutrophil count &lt;1,500/mm<sup>3</sup>, platelet count &lt;90,000/mm<sup>3</sup> or hemoglobin &lt;10 g/dL. Discontinue therapy (at least temporarily) if ANC &lt;500/mm<sup>3</sup> or platelet count &lt;25,000/mm<sup>3</sup>. Severe neutropenia and thrombocytopenia may occur with a greater incidence in HIV coinfected patients than monoinfected patients. Obtain CBC before treatment and monitor routinely during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: Serious cutaneous reactions, including vesiculobullous eruptions, Stevens-Johnson syndrome, and exfoliative dermatitis, have been reported with use, with or without ribavirin therapy; discontinue with signs or symptoms of severe skin reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Gastrointestinal hemorrhage, ulcerative and hemorrhagic/ischemic colitis (may be fatal) have been observed with interferon alfa treatment; may be severe and/or life-threatening; discontinue immediately if symptoms of colitis (eg, abdominal pain, bloody diarrhea, and/or fever) develop. Colitis generally resolves within 1 to 3 weeks of discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Hepatic decompensation and death have been associated with the use of alpha interferons including Pegasys, in cirrhotic chronic hepatitis C patients; patients coinfected with HIV and receiving antiretroviral therapy have shown an increased risk. Monitor hepatic function closely during use; discontinue immediately if decompensation occurs (Child-Pugh score &gt;6) in monoinfected patients and (Child-Pugh score &ge;6, class B and C) in patients coinfected with HIV. Instruct patients to avoid alcohol; may increase hepatic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) have been reported; prompt discontinuation and management is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: <b>[US Boxed Warning]: May cause or exacerbate life-threatening neuropsychiatric disorders; monitor closely; discontinue treatment with worsening or persistently severe signs/symptoms of neuropsychiatric disorders. In most cases these effects were reversible following discontinuation, but not all cases.</b> Neuropsychiatric adverse effects include depression, suicidal ideation, suicide attempt, homicidal ideation, drug overdose, and relapse of drug addiction, and may occur in patients with or without a prior history of psychiatric disorder. Avoid use in severe psychiatric disorders; use with extreme caution in patients with a history of depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: Decreased or loss of vision and retinopathy, including macular edema, optic neuritis, papilledema, retinal hemorrhages, retinal detachment (serous), cotton wool spots, and retinal artery or vein thrombosis, may occur or be aggravated during treatment; if any ocular symptoms occur during use, a complete eye exam should be performed promptly. Prior to use, all patients should have a visual exam and patients with preexisting disorders (eg, diabetic or hypertensive retinopathy) should have exams periodically during therapy. Discontinue if new or worsening ophthalmologic disorders occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Pancreatitis, including fatal cases, has been observed with alfa interferon and ribavirin therapy. Withhold treatment for suspected pancreatitis; discontinue therapy for confirmed pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary effects: May cause or aggravate dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis, which may result in potentially fatal respiratory failure; may recur upon rechallenge with interferons. Monitor closely. Discontinue with pulmonary infiltrates or evidence of impaired pulmonary function. Use with caution in patients with pulmonary dysfunction or a history of pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disease: <b> [US Boxed Warning]: May cause or exacerbate autoimmune disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of autoimmune disease. In most cases these effects were reversible following discontinuation, but not all cases.</b> Thyroiditis, thrombotic thrombocytopenic purpura, immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura), rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, myositis, hepatitis, and psoriasis have been reported with interferon therapy; use with caution in patients with autoimmune disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with prior cardiovascular disease; hypertension, supraventricular arrhythmias, chest pain, and MI have been observed with treatment. Patients with a history of significant or unstable cardiac disease should not receive combination treatment with ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; hyper/hypoglycemia have been reported; may require adjustments in antidiabetic medications; discontinue if unable to effectively manage diabetes with medication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: In hepatitis B patients, flares (transient and potentially severe increases in serum ALT) may occur during or after treatment; more frequent monitoring of LFTs and a dose reduction are recommended. Discontinue immediately if ALT elevation continues despite dose reduction or if increased bilirubin or hepatic decompensation occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infectious disorders: <b> [US Boxed Warning]: May cause or aggravate infectious disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of infectious disorders. In most cases these effects were reversible following discontinuation, but not all cases.</b> Serious and severe infections (bacterial, viral, and fungal), some fatal, have been reported with treatment. Interferon therapy is commonly associated with flu-like symptoms, including fever; rule out other causes/infection with persistent or high fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic disorders: <b>[US Boxed Warning]: May cause or aggravate ischemic disorders and hemorrhagic cerebrovascular events; monitor closely; discontinue treatment in patients with worsening or persistent ischemia. In most cases these effects were reversible following discontinuation, but not all cases</b>. Has been reported in patients without risk factors for stroke.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal dysfunction (CrCl &lt;30 mL/minute); dosage adjustment recommended; monitor for signs/symptoms of toxicity (dosage adjustment required if toxicity occurs).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Clinical practice chronic hepatitis B treatment guidelines do not recommend use in patients with uncontrolled seizures (AASLD [Terrault 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Use with caution in patients with preexisting thyroid disease; thyroid disorders (hyper- or hypothyroidism) or exacerbations have been reported; discontinue if unable to effectively manage with medication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; certain adverse effects (eg, neuropsychiatric, cardiac, flu-like reactions) may be more severe.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Growth velocity (height and weight) was decreased in children with or without combination treatment with ribavirin, during the length of treatment. In clinical studies, decreases were noted in weight and height for age z-scores and normative growth curve percentiles. Following treatment, rebound growth and weight gain occurred in most patients; however, a small percentage did not. For most children with hepatitis C, posttreatment recovery in growth at 2 years posttreatment was maintained to 6 years posttreatment; no data are available on long term follow-up for children with hepatitis B. Growth should be closely monitored in children during therapy and posttreatment until growth catch-up has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variability: <b>Due to differences in dosage, patients should not change brands of interferon without the concurrence of their health care provider.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hepatitis C:</i> Combination therapy with ribavirin or monotherapy for the treatment of chronic hepatitis C is no longer a recommended treatment regimen (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hepatitis B:</i> Hepatitis B genotypes A and B are more likely to achieve HBeAg and HBsAg loss with peg-interferon than non-A/B genotypes. For patients with hepatitis B coinfected with hepatitis delta virus (HDV), pegylated interferon is the only effective therapy (AASLD [Terrault 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206913\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206874\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10136&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Interferons (Alfa) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2a.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telbivudine: Peginterferon Alfa-2a may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206889\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use with ribavirin is contraindicated in pregnant women and males whose female partners are pregnant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Combination therapy with ribavirin may cause birth defects and/or fetal mortality; avoid pregnancy in females and female partners of male patients.</b> Pregnancy status should be assessed prior to therapy. Female patients of childbearing potential and male patients with female partners of childbearing potential must use 2 forms of contraception along with monthly pregnancy tests during therapy and for 6 months after therapy has been discontinued. If used in combination with ribavirin, all warnings related to the use of ribavirin and pregnancy and/or contraception should be followed.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Based on adverse events observed in animal reproduction studies, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid (Lebon 1982). In vitro administration studies have reported that when administered to the mother, it does not cross the placenta (Waysbort 1993).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The HHS Perinatal HIV Guidelines do not recommend that peginterferon-alfa be used during pregnancy (HHS [perinatal] 2016). Mother-to-child transmission of HCV does not occur if the woman is not viremic, therefore, HCV-infected women of childbearing potential should postpone pregnancy until therapy is complete. Treatment of HCV is not recommended for women who are already pregnant (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5366118\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Breast milk samples obtained from a lactating mother prior to and after administration of interferon alfa-2b showed that interferon alfa is present in breast milk and administration of the medication did not significantly affect endogenous levels (Kumar 2000). Breastfeeding is not linked to the spread of hepatitis C virus (ACOG, 2007); however, if nipples are cracked or bleeding, breastfeeding is not recommended (CDC [Workowski 2015]). Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug. Mothers coinfected with HIV are discouraged from breastfeeding to decrease potential transmission of HIV (HHS [perinatal] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206890\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid ethanol use in patients with hepatitis C virus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206878\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clinical studies tested as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pediatric patients: Hematologic and biochemical assessments were made at weeks 1, 3, 5, and 8, and then every 4 weeks thereafter; TSH measured every 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: CBC (including hemoglobin, WBC, and platelets) and chemistries (including liver function tests and uric acid) measured at weeks 1, 2, 4, 6, and 8, and then every 4-6 weeks (more frequently if abnormal); TSH measured every 12 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">In addition, the following baseline values were used as entrance criteria in adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &ge;90,000/mm<sup>3</sup> (as low as 75,000/mm<sup>3</sup> in patients with cirrhosis or 70,000/mm<sup>3</sup> in patients with CHC coinfected with HIV)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &ge;1,500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine &lt;1.5 times ULN</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">TSH and T<sub>4</sub> within normal limits or adequately controlled</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CD4<sup>+</sup> cell count &ge;200 cells/mm<sup>3</sup> or CD4<sup>+</sup> cell count &ge;100 cells/mm<sup>3</sup>, but &lt;200 cells/mm<sup>3</sup> <b>and </b> HIV-1 RNA &lt;5,000 copies/mL in CHC patients coinfected with HIV</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemoglobin &ge;12 g/dL for women and &ge;13 g/dL for men in CHC monoinfected patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemoglobin &ge;11 g/dL for women and &ge;12 g/dL for men in CHC patients coinfected with HIV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Serum HCV RNA levels (pretreatment, 12- and 24 weeks after therapy initiation, 24 weeks after completion of therapy). <b>Note:</b> Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotype 1) who fail to achieve an early virologic response (EVR) (defined as &ge;2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA. Treat patients with HCV (genotypes 2,3) for 24 weeks (if tolerated) and then evaluate HCV RNA levels (Ghany 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Prior to treatment, pregnancy screening should occur for women of childbearing age who are receiving treatment or who have male partners who are receiving treatment. In combination therapy with ribavirin, pregnancy tests should continue monthly up to 6 months after discontinuation of therapy. Evaluate for depression and other psychiatric symptoms before and during therapy; baseline eye examination and periodically in patients with baseline disorders; baseline echocardiogram in patients with cardiac disease. In children, growth velocity and weight should be monitored during and periodically after combination therapy is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Alternate recommendations (</i>\n      <i>AASLD [Terrault 2016]</i>\n      <i>): Chronic Hepatitis B:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">During therapy: CBC (monthly to every 3 months); TSH (every 3 months); monitor for autoimmune, ischemic, neuropsychiatric, and infectious complications.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206869\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Interferons inhibit cellular growth, alter the state of cellular differentiation, interfere with oncogene expression, alter cell surface antigen expression, increase phagocytic activity of macrophages, and augment cytotoxicity of lymphocytes for target cells. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206885\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 50-160 hours; increased with renal dysfunction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 72 to 96 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206888\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pegasys ProClick Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mcg/0.5 mL (0.5 mL): $1,225.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mcg/0.5 mL (0.5 mL): $1,225.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pegasys Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mcg/0.5 mL (0.5 mL): $1,225.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mcg/mL (1 mL): $1,225.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206891\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Optipeg-A (BD);</li>\n      <li>Pegasys (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, ET, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VE, VN);</li>\n      <li>Pegasys PFS (KR);</li>\n      <li>Pegferon (BD);</li>\n      <li>Peghasis (UA);</li>\n      <li>Pegin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2007, 110(4):941-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/17906043/pubmed\" target=\"_blank\" id=\"17906043\">17906043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org. Updated September 21, 2017. Accessed September 26, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. <i>MMWR Recomm Rep</i>. 2010;59(RR-12):1-110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/21160459/pubmed\" target=\"_blank\" id=\"21160459\">21160459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dienstag JL and McHutchison JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo; <i>Gastroenterology</i>, 2006, 130(1):225-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/16401485/pubmed\" target=\"_blank\" id=\"16401485\">16401485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fried MW, Shillman ML, Reddy KR, et al, &ldquo;Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection,&rdquo; <i>N Engl J Med</i>, 2002, 347:975-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/12324553/pubmed\" target=\"_blank\" id=\"12324553\">12324553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated April 29, 2016. Accessed May 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al, &quot;Peginterferon for Chronic Hepatitis C in Children Affects Growth and Body Composition: Results From the Pediatric Study of Hepatitis C (PEDS-C) Trial,&quot; <i>Hepatology</i>, 2012, 56(2):523-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/22383118/pubmed\" target=\"_blank\" id=\"22383118\">22383118</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. <i>J Hum Lact</i>. 2000;16(3):226-228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/11153157/pubmed\" target=\"_blank\" id=\"11153157\">11153157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lebon P, Girard S, Thepot F, et al, &ldquo;The Presence of Alpha-Interferon in Human Amniotic Fluid,&rdquo; <i>J Gen Virol</i>, 1982, 59(Pt 2):393-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/6176680/pubmed\" target=\"_blank\" id=\"6176680\">6176680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcellin P, Lau GK, Bonino F, et al, &quot;Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients With HBeAg-Negative Chronic Hepatitis B,&quot; <i>N Engl J Med</i>, 2004, 351(12):1206-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/15371578/pubmed\" target=\"_blank\" id=\"15371578\">15371578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KF, Rodrigue JR, Gonzalez-Peralta RP, et al, &ldquo;Design of the PEDS-C Trial: Pegylated Interferon +/- Ribavirin for Children With Chronic Hepatitis C Viral Infection,&rdquo; <i>Clin Trials</i>, 2007, 4(6):661-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/18042575/pubmed\" target=\"_blank\" id=\"18042575\">18042575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pegasys (peginterferon alfa-2a) [prescribing information]. South San Francisco, CA: Genentech, Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al, &ldquo;The Combination of Ribavirin and Peginterferon is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C,&rdquo; <i>Gastroenterology</i>, 2011, 140(2):450-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/21036173/pubmed\" target=\"_blank\" id=\"21036173\">21036173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. <i>Hepatology</i>. 2016;63(1):261-283. doi: 10.1002/hep.28156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/26566064/pubmed\" target=\"_blank\" id=\"26566064\">26566064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al, &quot;Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients,&quot; <i>N Engl J Med</i>, 2004, 351(5):438-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/15282351/pubmed\" target=\"_blank\" id=\"15282351\">15282351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waysbort A, Giroux M, Mansat V, et al, &ldquo;Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,&rdquo; <i>Antimicrob Agents Chemother</i>, 1993, 37(6):1232-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/8328774/pubmed\" target=\"_blank\" id=\"8328774\">8328774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10136 Version 160.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709197\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206899\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206900\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F206919\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F206903\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F15043485\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062247\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F206904\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F206905\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F3022885\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206881\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F206867\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874941\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F206883\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F206882\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206872\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206886\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206870\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F206913\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206874\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206889\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5366118\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F206890\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F206878\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206869\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F206885\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F206888\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206891\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10136|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-patient-drug-information\" class=\"drug drug_patient\">Pegylated interferon (peginterferon) alfa-2a: Patient drug information</a></li><li><a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information\" class=\"drug drug_pediatric\">Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information</a></li></ul></div></div>","javascript":null}